Impact of CD14++CD16+ monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients. (February 2018)

• Record Type: Journal Article
• Authors: Yamamoto, Hiroyuki; Yoshida, Naofumi; Shinke, Toshiro; Otake, Hiromasa; Kuroda, Masaru; Sakaguchi, Kazuhiko; Hirota, Yushi; Toba, Takayoshi; Takahashi, Hachidai; Terashita, Daisuke; Uzu, Kenzo; Tahara, Natsuko; Shinkura, Yuto; Kuroda, Kouji; Nagasawa, Yoshinori; Nagano, Yuichiro; Tsukiyama, Yoshiro; Yanaka, Ken-ichi; Emoto, Takuo; Sasaki, Naoto; Yamashita, Tomoya; Ogawa, Wataru; Hirata, Ken-ichi
• Is Part Of: Atherosclerosis. Volume 269(2018)
• Page Start: 245
• Page End: 251
• Publication Date: 2018-02
• Subjects: CD14++CD16+ monocytes -- Thin-cap fibroatheroma -- Fibrous cap thickness -- Coronary plaque vulnerability -- Optical coherence tomography -- Glucose fluctuation; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2018.01.010
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: This study examined the impact of CD14 ++ CD16 + monocytes on coronary plaque vulnerability, as assessed by optical coherence tomography (OCT), and investigated their association with daily glucose fluctuation. Although increased CD14 ++ CD16 + monocyte levels have been reported to increase cardiovascular events, their impact on coronary plaque vulnerability in coronary artery disease (CAD) patients with or without diabetes mellitus (DM) remains unclear. Methods: This prospective observational study included 50 consecutive patients with CAD, receiving lipid-lowering therapy and undergoing coronary angiography and OCT. Patients were divided into 3 tertiles according to the CD14 ++ CD16 + monocyte percentages assessed by flow cytometry. Standard OCT parameters were assessed for 97 angiographically intermediate lesions (diameter stenosis: 30–70%). Daily glucose fluctuation was analyzed by measuring the mean amplitude of glycemic excursion (MAGE). Results: CD14 ++ CD16 + monocytes negatively correlated with fibrous cap thickness (r = −0.508, p < 0.01). The presence of thin-cap fibroatheroma (TCFA) was increased stepwise according to the tertile of CD14 ++ CD16 + monocytes (0 [tertile 1] vs. 5 [tertile 2] vs. 10 [tertile 3], p < 0.01). CD14 ++ CD16 + monocytes were a significant determinant of TCFA (OR 1.279, p = 0.001). In non-DM patients, a significant relationship was found between CD14 ++ CD16 + monocytes and MAGE (r = 0.477, p = 0.018). Conclusions: CD14 ++ CD16 + monocytes were associated with coronary plaque vulnerability in CAD patients with well-regulated lipid levels both in DM and non-DM patients. Cross-talk between glucose fluctuation and CD14 ++ CD16 + monocytes may enhance plaque vulnerability, particularly in non-DM patients. CD14 ++ CD16 + monocytes could be a possible therapeutic target for coronary plaque stabilization. Highlights: Fibrous cap thickness was negatively correlated with CD14 ++ CD16 + monocyte levels. CD14 ++ CD16 + monocyte levels was an independent predictor for TCFA. MAGE scores were significantly higher in patients with TCFA than in those without. CD14 ++ CD16 + monocyte levels correlated with MAGE score in non-DM patients.